

Supplementary Table S2

BRCA1 and BRCA2 status in olaparib resistant and sensitive CRC cell lines. We considered the 10 most sensitive and the 10 most resistant (olaparib 5 μ M) cell lines and analyzed their BRCA1 and BRCA2 genetic profiles with a clinical-grade test. VUS: Variant of Unknown Significance.

n.	Name	NGS BRCA1	NGS BRCA2	Variants (HGVS nomenclature)
1	KP363T	WT	WT	
2	OUMS-23	WT	WT	
3	HROC39	WT	WT	
4	HROC69	WT	7 VUS	B2-c.302T>G p.(Phe101Cys), B2-c.686T>C p.(Val229Ala), B2-c.2090A>C p.(Lys697Thr), B2-4531G>A p.(Glu1511Lys), B2-c.4790C>A p.(Ser1597Tyr), B2-c.5282G>A p.(Gly1761Glu), B2-c.7436-9C>A p. (all 50%)
5	HROC277	WT	WT	
6	HROC334	1 VUS	WT	B1-c.3708T>G p.(Asn1236Lys) (50%)
7	HROC278Met	WT	WT	
8	HROC278	WT	WT	
9	OXCO-3	1 VUS	WT	B1-c.2542G>Cp.(Glu848Gln) (around 25%)
10	SKCO1	WT	WT	
11	HROC239	WT	WT	
12	COGA5	WT	WT	
13	COLO201	WT	WT	
14	CAR1	WT	WT	
15	HUTU80	WT	WT	
16	SNU977	WT	WT	
17	HCC2998	WT	7 VUS	B2-c.862C>T p.(Pro288Ser), B2-c.2451G>T p.(Lys817Asn), B2-c.2943A>C p.(Lys981Asn), B2-c.3529G>A p.(Asp1177Asn), B2-c.6406T>G p.(Leu2136Val), c.8686C>T p.(Arg2896Cys), B2-c.10024G>A p.(Glu3342Lys) (all 66%)
18	CX1	WT	1 PAT	B2-c.6772G>T p.(Glu2258*) (around 25%)
19	HROBMCO1	WT	WT	
20	OXCO-1	WT	WT	